文献速递肿瘤 PET/CT

基于机器学习的68Ga-PSMA-11 PET/CT对原发性前列腺癌患者前列腺内不可见病灶的预测

Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68 Ga-PSMA-11 PET/CT in patients with primary prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-11-30

本研究回顾性纳入两家机构中68Ga-PSMA PET/CT图像上前列腺内病灶阴性(不可见)的患者,机构1(2017–2020年)为训练集,机构2(2019–2020年)为外部测试集,构建基于标准PET、延迟PET及两者联合的三种随机森林影像组学模型。测试集中三种模型AUC分别为0.903、0.856、0.925,均高于PSAD的0.662(P=.007、P=.045、P=.005),提示基于68Ga-PSMA-11 PET的影像组学随机森林模型有助于预测前列腺内不可见病灶。

要点

  • 训练集64例(前列腺癌39例、良性前列腺疾病25例),外部测试集36例(前列腺癌21例、良性15例)。
  • 十折交叉验证三种随机森林模型平均AUC为0.87、0.86、0.91。
  • 测试集三种模型AUC均高于PSAD(0.662),P值分别为.007、.045、.005。

核心结论

  • 基于68Ga-PSMA-11 PET影像组学特征构建的随机森林模型有助于准确预测原发性前列腺癌患者68Ga-PSMA-11 PET上的前列腺内不可见病灶,诊断性能优于PSAD。

研究设计与样本

  • 回顾性研究,纳入两家机构中68Ga-PSMA PET/CT图像上前列腺内病灶阴性的患者,机构1(2017–2020年)为训练集,机构2(2019–2020年)为外部测试集。
  • 利用标准PET图像、延迟PET图像及两者联合提取的特征分别构建三种随机森林模型,并进行十折交叉验证。
  • 测试阶段以外部测试集评估三种随机森林模型及PSA密度(PSAD,截断值0.15 ng/ml/ml),计算并比较AUC。

主要发现

  • 训练集共64例(前列腺癌39例、良性前列腺疾病25例),测试集共36例(前列腺癌21例、良性前列腺疾病15例)。
  • 十折交叉验证三种随机森林模型平均AUC分别为0.87(95%CI:0.72,1.00)、0.86(95%CI:0.63,1.00)、0.91(95%CI:0.69,1.00)。
  • 测试集中三种随机森林模型AUC分别为0.903(95%CI:0.830,0.975)、0.856(95%CI:0.748,0.964)、0.925(95%CI:0.838,1.00),PSAD的AUC为0.662(95%CI:0.510,0.813)。
  • 三种影像组学模型AUC均高于PSAD(0.903、0.856、0.925 vs. 0.662),P值分别为.007、.045、.005。

关键数值与推荐

  • PSAD截断值为0.15 ng/ml/ml,测试集AUC为0.662(95%CI:0.510,0.813)。
  • 标准PET、延迟PET及联合图像构建的随机森林模型测试集AUC分别为0.903、0.856、0.925。
  • 三种影像组学模型与PSAD的AUC比较P值分别为.007、.045、.005。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 68 Ga-PSMA PET/CT has high specificity and sensitivity for the detection of both intraprostatic tumor focal lesions and metastasis. However, approximately 10% of primary prostate cancer are invisible on PSMA-PET (exhibit no or minimal uptake). In this work, we investigated whether machine learning-based radiomics models derived from PSMA-PET images could predict invisible intraprostatic lesions on 68 Ga-PSMA-11 PET in patients with primary prostate cancer. METHODS: In this retrospective study, patients with or without prostate cancer who underwent 68 Ga-PSMA PET/CT and presented negative on PSMA-PET image at either of two different institutions were included: institution 1 (between 2017 and 2020) for the training set and institution 2 (between 2019 and 2020) for the external test set. Three random forest (RF) models were built using selected features extracted from standard PET images, delayed PET images, and both standard and delayed PET images. Then, subsequent tenfold cross-validation was performed. In the test phase, the three RF models and PSA density (PSAD, cut-off value: 0.15 ng/ml/ml) were tested with the external test set. The area under the receiver operating characteristic curve (AUC) was calculated for the models and PSAD. The AUCs of the radiomics model and PSAD were compared. RESULTS: A total of 64 patients (39 with prostate cancer and 25 with benign prostate disease) were in the training set, and 36 (21 with prostate cancer and 15 with benign prostate disease) were in the test set. The average AUCs of the three RF models from tenfold cross-validation were 0.87 (95% CI: 0.72, 1.00), 0.86 (95% CI: 0.63, 1.00), and 0.91 (95% CI: 0.69, 1.00), respectively. In the test set, the AUCs of the three trained RF models and PSAD were 0.903 (95% CI: 0.830, 0.975), 0.856 (95% CI: 0.748, 0.964), 0.925 (95% CI:0.838, 1.00), and 0.662 (95% CI: 0.510, 0.813). The AUCs of the three radiomics models were higher than that of PSAD (0.903, 0.856, and 0.925 vs. 0.662, respectively; P = .007, P = .045, and P = .005, respectively). CONCLUSION: Random forest models developed by 68 Ga-PSMA-11 PET-based radiomics features were proven useful for accurate prediction of invisible intraprostatic lesion on 68 Ga-PSMA-11 PET in patients with primary prostate cancer and showed better diagnostic performance compared with PSAD.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yi Z, Hu S, Lin X, et al. Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68 Ga-PSMA-11 PET/CT in patients with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34845536. doi:10.1007/s00259-021-05631-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。